CISH and metastatic malignant neoplasm: A study genetically engineered antigen‐specific TIL to inhibit the expression of the checkpoint CISH in T cells by efficiently editing the genes encoding the intracellular checkpoint target CISH using CRISPR/Cas9 (NCT04426669), inhibiting the antitumor activity of lymphocytes from patients with metastatic cancers, in order to evaluate the genetically engineered T cell therapy safety and efficacy in treating patients with solid tumors of the GI tract in the context of novel checkpoint inhibition.